Australian and New Zealand clinical practice guidelines for the treatment of depression

References

• Ellis P M, Smith D AR. Treating depression: the beyondblue guidelines for treating depression in primary care. ‘Not so much what you do but that you keep doing it’. Medical Journal of Australia 2002; 176(Suppl.)S77–S83
   PubMedGoogle Scholar
• National Health Committee. Guidelines for the treatment and management of depression by primary healthcare professionals. Ministry of Health, Wellington 1996
   Google Scholar
• Health and Medical Research Council. Getting up from feeling down: young people and depression. National Health and Medical Research Council, Canberra 1997
   Google Scholar
• Andrews G. Brief report provided to the New Zealand Treasury on the prevalence and disability of DSM-IV disorders from the 1997 Australian National Survey of Mental Health and Well-being. New Zealand Treasury, Wellington 2000
   Google Scholar
• McLennan W. Mental health and wellbeing: profile of adults, Australia 1997. Australian Bureau of Statistics, Canberra 1998
   Google Scholar
• Wells K, Stewart A, Hays R D, et al. The functioning and well-being of depressed patients: results from the Medical Outcomes Study. Journal of the American Medical Association 1989; 262: 914–919
   PubMed Web of Science ®Google Scholar
• Hays R D, Well K B, Sherbourne C D, Rodgers W, Spritzer K. Functioning and well-being outcomes of patients with depression compared with chronic general medical illnesses. Archives of General Psychiatry 1995; 52: 11–19
   PubMed Web of Science ®Google Scholar
• Murray C JL, Lopez A D. The global burden of disease: a comprehensive assessment of mortality and disability from disease, injuries and risk factors in 1990 and projected to 2020, C JL Murray, A D Lopez. Harvard University Press, Cambridge, MA 1996
   Google Scholar
• Goldberg D. The recognition of psychiatric illness by non-psychiatrists. Australian and New Zealand Journal of Psychiatry 1984; 18: 128–133
   PubMed Web of Science ®Google Scholar
• Keller M B. Under-recognition and under-treatment by psychiatrists and other healthcare professionals. Archives of Internal Medicine 1990; 150: 946–948
   PubMedGoogle Scholar
• McGee R, Feehan M, Williams S, Anderson J. DSM-III disorders from age 11–15 years. Journal of the American Academy of Child and Adolescent Psychiatry 1992; 31: 50–59
   PubMed Web of Science ®Google Scholar
• Feehan M, McGee R, Raja S N, Willimas S M. DSM-III disorders in New Zealand 18 year olds. Australian and New Zealand Journal of Psychiatry 1994; 28: 87–99
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), 4th edn. American Psychiatric Press, Washington, DC 1994
   Google Scholar
• Mulrow C D, Williams J W, Trivedi M, Chiquette E, Aguilar C, Cornell J E. Treatment of depression: Newer pharmacotherapies: AHCPR. Agency for Healthcare Policy and Research, Rockville, MD 1999
   Google Scholar
• Keller M B, Lavori P W. Double depressive disorder, major depressive disorder and dysthymic disorder. Distinct entities or different phases of a single disorder?. Psychopharmacology Bulletin 1984; 20: 399–402
   PubMedGoogle Scholar
• Keller M B, Lavori P W, Mueller T I, et al. Time to recovery, chronicity and levels of psychopathology in major depression. Archives of General Psychiatry 1992; 49: 809–816
   PubMed Web of Science ®Google Scholar
• Lee A S, Murray R M. The long-term outcome of Maudsley depressives. British Journal of Psychiatry 1998; 153: 741–751
   Google Scholar
• Judd L L, Hagop S A, Maser J D, et al. A prospective 12 year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Archives of General Psychiatry 1998; 55: 694–700
   PubMed Web of Science ®Google Scholar
• Thase M E, Sullivan L R. Relapse and recurrence of depression: a practical approach for prevention. CNS Drugs 1995; 4: 261–277
   Web of Science ®Google Scholar
• Brodaty H, Luscombe G, Peisah C, Anstey K, Andrews G. A 25 year longitudinal, comparison study of the outcome of depression. Psychological Medicine 2001; 31: 1347–1359
   PubMed Web of Science ®Google Scholar
• Inskip H, Harris C, Barraclough B. Lifetime risk of suicide for affective disorder, alcoholism and schizophrenia. British Journal of Psychiatry 1998; 172: 35–37
   PubMed Web of Science ®Google Scholar
• Black D W, Winokur G, Nasralla A. Effects of psychosis on suicide risk in 1,593 patients with unipolar and bipolar affective disorders. American Journal of Psychiatry 1988; 145: 849–852
   PubMed Web of Science ®Google Scholar
• Hyman S, Arana G W. Suicide and affective disorder. Sucide: understanding and responding, D BH Jacobs. International University Press, Madison 1990; 171–181
   Google Scholar
• Jamison K R. Suicide and bipolar disorder. Annals of the New York Academy of Science 1986; 487: 301–315
   PubMedGoogle Scholar
• Rutz W, von Knorring L, Walinder J. Frequency of suicide on Gotland after systematic postgraduate education of general practitioners. Acta Psychiatrica Scandinavica 1989; 80: 151–154
   PubMed Web of Science ®Google Scholar
• Isacsson G, Gergman U, Rich C L. Epidemiological data suggest antidepressants reduce suicide risk among depressives. Journal of Affective Disorders 1996; 41: 1–8
   PubMed Web of Science ®Google Scholar
• Isacsson G, Holmgren P, Druid H, Bergman U. Psychotropics and suicide prevention: Implications from toxicological screening of 5281 suicides in Sweden 1992–94. British Journal of Psychiatry 1999; 174: 259–265
   PubMed Web of Science ®Google Scholar
• Oquendo M, Malone K, Ellis S P, Sackeim H A, Mann J J. Inadequacy of antidepressant treatment for patients with major depression who are at risk for suicidal behavior. American Journal of Psychiatry 1999; 156: 190–194
   PubMed Web of Science ®Google Scholar
• Appleby L, Cooper J, Amos T, Faragher B. Psychological autopsy study of suicides by people under 35. British Journal of Psychiatry 1999; 175: 168–174
   PubMed Web of Science ®Google Scholar
• Mann J, Waternaux C, Hass G L, Malone K M. Toward a clinical model of suicidal behavior in psychiatric patients. American Journal of Psychiatry 1999; 156: 181–189
   PubMed Web of Science ®Google Scholar
• Keitner G, Ryan C, Miller I W, Kohn R, Bishop D S, Epstein N B. Role of the family in recovery and major depression. American Journal of Psychiatry 1995; 152: 1002–1008
   PubMed Web of Science ®Google Scholar
• Weich S, Lewis G. Poverty, unemployment and common mental disorders: population based cohort study. British Medical Journal 1998; 317: 115–119
   PubMed Web of Science ®Google Scholar
• Kendler K S, Kessler R C, Neale M C, Heath A C, Eaves L J. The prediction of Major Depression in women: Towards an integrated aetiological model. American Journal of Psychiatry 1993; 150: 863–870
   Google Scholar
• Romans S E, Walton V A, McNoe B, Herbison G P, Mullen P E. Otago women's health survey 30 month follow-up I: Onset patterns of non-psychotic psychiatric disorder. British Journal of Psychiatry 1993; 163: 733–738
   PubMed Web of Science ®Google Scholar
• Romans S E, Walton V A, McNoe B, Herbison G P, Mullen P E. Otago women's health survey 30 month follow-up II. Remission patterns of non-psychotic psychiatric disorder. British Journal of Psychiatry 1993; 163: 739–746
   PubMedGoogle Scholar
• Brown G W, Moran P. Clinical and psychosocial origins of chronic depressive episodes: a community survey. British Journal of Psychiatry 1994; 165: 447–456
   PubMed Web of Science ®Google Scholar
• Brown G W, Harris T O, Hepworth C, Robinson R. Clinical and psychosocial origins of chronic depressive episodes. II: A patient enquiry. British Journal of Psychiatry 1994; 165: 457–465
   PubMed Web of Science ®Google Scholar
• Thase M E. Treatment of severe depression. Journal of Clinical Psychiatry 2000; 61(Suppl.1)17–25
   PubMed Web of Science ®Google Scholar
• Bebbington P, Katz R, McGuffin P, et al. The risk of minor depression before the age of 65: results from a community survey. Psychological Medicine 1989; 24: 707–718
   Google Scholar
• Weissmann M M, Leaf D J, Tischler G L, et al. Affective disorders in five United States communities. Psychological Medicine 1988; 18: 141–153
   PubMedGoogle Scholar
• Joyce P R, Oakley-Browne M A, Wells J E, Bushnell J A, Hornblow A R. Birth cohort trends in major depression: increasing rates and earlier onset in New Zealand. Journal of Affective Disorders 1990; 18: 83–89
   PubMed Web of Science ®Google Scholar
• Klerman G L, Weissmann M M. Increasing rates of depression. Journal of the American Medical Association 1989; 261: 2229–2235
   PubMed Web of Science ®Google Scholar
• Katon W, Ciechanowski P. Impact of major depression on chronic medical illness. Journal of Psychosomatic Medicine 2002; 53: 859–863
   Google Scholar
• Fairfield K M, Libman H, Davis R B, Eisenberg D M, Beckett A, Phillips R S. Brief communication: detecting depression: providing high quality primary care for HIV-infected patients. American Journal of Medical Quality 2001; 16: 71–74
   PubMed Web of Science ®Google Scholar
• Zorrilla E P, McKay J R, Luborsky L, Schmidt K. Relation of stressors and depressive symptoms to clinical progression of viral illness [Comment]. American Journal of Psychiatry 1996; 154: 718
   Google Scholar
• Singh N, Squier C, Sivek C, Wagener M M, Yu V L. Psychological stress and depression in older patients with intravenous drug use and human immunodeficiency virus infection: implications for intervention. International Journal of STD and AIDS 1997; 8: 251–255
   PubMed Web of Science ®Google Scholar
• McClure J B, Catz S L, Prejean J, Brantley P J, Jones G N. Factors associated with depression in a heterogeneous HIV-infected sample. Journal of Psychosomatic Research 1996; 40: 407–415
   PubMed Web of Science ®Google Scholar
• Rampello L, Chiechio S, Raffaele R, Vecchio I, Nicoletti F. The SSRI, citalopram, improves bradykinesia in patients with Parkinson's disease treated with 1-dopa. Clinical Neuropharmacology 2002; 25: 21–24
   PubMed Web of Science ®Google Scholar
• Ruoff G E. Depression in the patient with chronic pain. Journal of Family Practice 1996; 43(Suppl.)S25–S33
   Google Scholar
• Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 1960; 23: 56–62
   PubMed Web of Science ®Google Scholar
• Mietinnen O, Nurminnen M. Comparative analysis of two rates. Statistics in Medicine 1985; 17: 873–890
   Google Scholar
• Radloff L S. The CES-D scale: a self report Major Depressive Disorder scale for research in the general population. Applied Psychological Measurement 1977; 1: 385–401
   Web of Science ®Google Scholar
• Doganay Z, Sunter A T, Guz H, et al. Climatic and diurnal variation in suicide attempts in the, E.D. American Journal of Emergency Medicine 2003; 21: 271–275
   PubMed Web of Science ®Google Scholar
• Preti A, Miotto P. Diurnal variation in suicide by age and gender in Italy. Journal of Affective Disorders 2001; 65: 253–261
   PubMed Web of Science ®Google Scholar
• Williams R, Edwards R A, Newburn G M, et al. A double-blind comparison of moclobemide and fluoxetine in the treatment of depressive disorders. International Clinical Psychopharmacology 1993; 7: 155–158
   PubMedGoogle Scholar
• Khan A, Leventhal R, Khan S R, Brown W A. Severity of depression and response to antidepressants and placebo: An analysis of the food and drug administration database. Journal of Clinical Psychopharmacology 2002; 22: 40–45
   PubMed Web of Science ®Google Scholar
• Thase M E, Rush A J, Howland R H, et al. Double-blind switch study of imipramine or sertraline treatment of anti-depressant chronic depression. Archives of General Psychiatry 2002; 59: 233–239
   PubMed Web of Science ®Google Scholar
• Harris T, Brown G W, Robinson R. Befriending as an intervention for chronic depression among women in an inner city. 1: Randomized controlled trial. British Journal of Psychiatry 1999; 174: 219–224
   PubMed Web of Science ®Google Scholar
• Harris T, Brown G W, Robinson R. Befriending as an intervention for chronic depression among women in an inner city. 2: Role of fresh-start experiences and baseline psychosocial factors in remission from depression. British Journal of Psychiatry 1999; 174: 225–232
   PubMed Web of Science ®Google Scholar
• Mynors-Wallis L M, Gath D H, Lloyd-Thomas A R, et al. Randomised controlled trial comparing problem solving treatment with amitriptyline and placebo for major depression in primary care. British Medical Journal 1995; 310: 441–445
   PubMed Web of Science ®Google Scholar
• Mynors-Wallis L M, Gath D H, et al. Randomised controlled trial of problem solving treatment antidepressant medication and combined treatment for major depression in primary care. British Medical Journal 2000; 320: 26–30
   PubMed Web of Science ®Google Scholar
• Barkham M, Hardy G E. Counselling and interpersonal therapies for depression: towards an evidence base. British Medical Bulletin 2001; 57: 115–132
   PubMed Web of Science ®Google Scholar
• King M, Sibbald B, Ward E, et al. Executive summary. Randomised controlled trial of non-directive counselling, cognitive-behaviour therapy and usual general practitioner care in the management of depression as well as mixed anxiety and depression in primary care. Health Technology Assessment 2000; 4: 1–83
   PubMedGoogle Scholar
• Corruble E, Guelfi J D. Does increasing dose improve efficacy with poor antidepressant response: a review. Acta Psychiatrica Scandinavica 2000; 101: 343–348
   PubMed Web of Science ®Google Scholar
• Parker G. ‘New’ and ‘old’ antidepressants. all equal in the eyes of the lore?. British Journal of Psychiatry 2001; 179: 95–96
   PubMed Web of Science ®Google Scholar
• Murphy G E, Simons A D, Wetzel R D, et al. Cognitive therapy and pharmacotherapy. Singly and together in the treatment of depression. Archives of General Psychiatry 1984; 41: 33–41
   PubMed Web of Science ®Google Scholar
• Kellor M B, McCullough J P, Klein D N, et al. A comparison of nefazadone, the cognitive behavioral-analysis system of psychotherapy and their combination for the treatment of chronic depression. New England Journal of Medicine 2000; 342: 1462–1470
   PubMedGoogle Scholar
• Hollon S D, DeRubeis R J, Evans M D, et al. Cognitive therapy and pharmacotherapy for depression. Singly and in combination. Archives of General Psychiatry 1992; 49: 774–781
   PubMed Web of Science ®Google Scholar
• Ninan P T, Rush J, Crits-Christoph P, et al. Symptomatic and syndromal anxiety in chronic forms of major depression: effects of nefazodone, cognitive behavioral anaylsis system of psychotherapy, and their combination. Journal of Clinical Psychiatry 2002; 63: 434–441
   PubMedGoogle Scholar
• American Psychiatric Association. The practice of electroconvulsive therapy: Recommendations for treatment, training and privileging. American Psychiatric Press, Washington, DC 1990
   Google Scholar
• Freeman C P. The ECT handbook. Gaskell, London 1995, (Council report CR39)
   Google Scholar
• Mayur P M, Gangadhar B N, Subbakrishna D K, Janakiramaiah N. Discontinuation of antidepressant drugs during electroconvulsive therapy: a controlled study. Journal of Affective Disorders 2000; 58: 37–41
   PubMedGoogle Scholar
• Pare C M. The present status of monoamine oxidase inhibitors. British Journal of Psychiatry 1985; 146: 576–584
   PubMedGoogle Scholar
• Marino J R, Cosgrove G R. Neurosurgical treatment for neuropsychiatric illness. Psychiatric Clinics of North America 1997; 20: 933–943
   PubMedGoogle Scholar
• Kocsis J H, Schatzberg A, Rush A J, et al. Psychosocial outcomes following long-term, double-blind treatment of chronic depression with sertraline vs placebo. Archives of General Psychiatry 2002; 59: 723–728
   PubMed Web of Science ®Google Scholar
• Viguera A C, Baldessarini R J, Friedberg J. Discontinuing antidepressant treatment in major depression. Harvard Review of Psychiatry 1998; 5: 293–306
   PubMed Web of Science ®Google Scholar
• Michelson D, Fava M, Amsterdam J, et al. Interuption of selective serotonin reuptake inhibitor treatment. British Journal of Psychiatry 2000; 176: 363–368
   PubMed Web of Science ®Google Scholar
• Liebowitz M R, Quitkin F M, Stewart J W, et al. Antidepressant specificity in atypical depression. Archives of General Psychiatry 1988; 45: 129–137
   PubMed Web of Science ®Google Scholar
• Jarrett R B, Schaffer M, McIntire D, et al. Treatment of atypical depression with cognitive therapy or phenelzine: a double-blind, placebo-controlled trial. Archives of General Psychiatry 1999; 56: 431–437
   PubMed Web of Science ®Google Scholar
• Stewart J, Garfinkel R, Nunes E V, Donovan S, Klein D F. Atypical features and treatment response in the National Institute of Mental Health Treatment of Depression Collaborative Research Program. Journal of Clinical Psychopharmacology 1998; 18: 429–434
   PubMed Web of Science ®Google Scholar
• Quitkin F M, Stewart J W, McGrath P J, et al. Phenelzine versus imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAOI responders. American Journal of Psychiatry 1988; 145: 306–311
   PubMed Web of Science ®Google Scholar
• Quitkin F M, McGrath P J, Stewart J W, et al. Atypical depression, panic attacks, and response to imipramine and phenelzine: a replication. Archives of General Psychiatry 1990; 47: 935–941
   PubMedGoogle Scholar
• Kaskey G B, Nasr S, Meltzer H Y. Drug treatment in delusional depression. Psychiatry Research 1980; 1: 267–277
   Google Scholar
• Charney D S, Nelson J C. Delusional and non-delusional and unipolar depression: further evidence of distinct sub-types. American Journal of Psychiatry 1981; 138: 328–333
   PubMed Web of Science ®Google Scholar
• Brown R, Frances A, Kocsis J H, Mann J J. Psychotic vs non-psychotic depression: Comparison of treatment response. Journal of Nervous and Mental Disease 1982; 170: 635–637
   PubMedGoogle Scholar
• Minter R E, Mandel M R. The treatment of psychotic major depressive disorder with drugs and electroconvulsive therapy. Journal of Nervous and Mental Disease 1979; 167: 726–733
   PubMed Web of Science ®Google Scholar
• Spiker D G, Hanin I, Perel J M, Cofsky J E, Rossi A J, Sorisio D. Pharmacological treatment of delusional depressives. Psychopharmacology Bulletin 1982; 18: 184–186
   PubMedGoogle Scholar
• Spiker D G, Weiss J C, Dealy R S, et al. The pharmacological treatment of delusional depression. American Journal of Psychiatry 1985; 142: 430–435
   PubMed Web of Science ®Google Scholar
• Glassman A H, Kantor S J, Shostak M. Depression, delusions and drug response. American Journal of Psychiatry 1975; 132: 462–463
   Google Scholar
• Davidson J R, McLeod M N, Kurland A A, White H L. Antidepressant drug therapy in psychotic depression. British Journal of Psychiatry 1977; 131: 493–496
   PubMed Web of Science ®Google Scholar
• Avery D, Luborsky L. Depression treated with imipramine and ECT. The DeCarolis study reconsidered. American Journal of Psychiatry 1979; 136: 559–562
   PubMedGoogle Scholar
• Janakiramaiah N, Gangadhar B N, Nga Venkatesha Murthy P J, Harish M G, Subbakrishna D K, Vedamurthachar A. Antidepressant efficacy of Sudarshan Kriya Yoga (SKY) in melancholia: a randomized comparison with electroconvulsive therapy (ECT) and imipramine. Journal of Affective Disorders 2000; 57: 255–259
   PubMed Web of Science ®Google Scholar
• Jarrett R B, Kraft D, Doyle J, et al. Preventing recurrent depression using cognitive therapy with and without a continuation phase: a randomized clinical trial. Archives of General Psychiatry 2001; 58: 381–388
   PubMed Web of Science ®Google Scholar
• Katon W, Rutter C, Ludman E J, et al. A randomized trial of relapse prevention of depression in primary care. Archives of General Psychiatry 2001; 58: 241–247
   PubMed Web of Science ®Google Scholar
• Medicines in Pregnancy Working Party of the Australian Drug Evaluation Committee. Prescribing medicines in pregnancy. An Australian categorization of risk of drug use in pregnancy 4th edn. Therapeutic Goods Administration, Canberra 1999
   Google Scholar
• Dodds S, Buist A, Norman T R. Antidepressants and breast feeding: a review of the literature. Paediatric Drugs 2000; 2: 183–192
   PubMedGoogle Scholar
• Anonymous. Drugs and breast feeding. Prescribe International 2002; 11: 17
   PubMedGoogle Scholar
• Katona K, Livingston G. How well do antidepressants work in older people? A systematic review of the Number Needed to Treat. Journal of Affective Disorders 2002; 69: 47–52
   PubMed Web of Science ®Google Scholar
• Ballenger J C, Davidson J R, Lecrubier Y, et al. Consensus statement on depression, anxiety, and oncology. Journal of Clinical Psychiatry 2001; 62(Suppl.8)64–67
   PubMed Web of Science ®Google Scholar
• Gill D, Hatcher S. Database of systematic reviews (4). Cochrane Database of Systematic Reviews CD001312 2000
   Google Scholar
• Roose S P. Considerations for the use of antidepressants in patients with cardiovascular disease. American Heart Journal 2000; 140(Suppl.4)84–88
   PubMedGoogle Scholar
• Blanch J, Rousand A, Martinez E, et al. Impact of lipodystrophy on the quality of life of HIV-1-infected patients. Journal of Acquired Immune Deficiency Syndromes 2002; 31: 404–407
   PubMed Web of Science ®Google Scholar
• Sheard T, Maguire P. The effect of psychological interventions on anxiety and depression in cancer patients: results of two meta-analyses. British Journal of Cancer 1999; 80: 1770–1780
   PubMed Web of Science ®Google Scholar
• Brown E S, Suppes T. Mood symptoms during corticosteroid therapy: a review. Harvard Review of Psychiatry 1998; 5: 239–246
   PubMed Web of Science ®Google Scholar
• Penninx B WJH, Beekman A TF, Honig A, et al. Depression and cardiac mortality: Results from a community-based longitudinal study. Archives of General Psychiatry 2001; 58: 221–227
   PubMed Web of Science ®Google Scholar
• Glassman A H. Cardiovascular effects of antidepressant drugs: updated. Journal of Clinical Psychiatry 1998; 59(Suppl.15)13–18
   PubMedGoogle Scholar
• Swanson J R, O'Connor C M, Barton D, et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndromes. American Journal of Cardiology 2003; 92: 1271–1276
   PubMedGoogle Scholar
• Seiner S J, Mallya G. Treating depression in patients with cardiovascular disease. Harvard Review of Psychiatry 1999; 7: 85–93
   PubMedGoogle Scholar
• Rosenstein D L, Nelson J C, Jacobs S C. Seizures associated with antidepressants: a review. Journal of Clinical Psychiatry 1993; 54: 289–299
   PubMed Web of Science ®Google Scholar
• Lieberman E, Stoudemire A. Use of tricyclic antidepressants in patients with glaucoma. Psychosomatics 1987; 28: 145–148
   PubMedGoogle Scholar
• Sayal K S, Duncan-McConnell H W, Taylor D M. Psychotropic interactions with warfarin. Acta Psychiatrica Scandinavica 2000; 102: 250–255
   PubMed Web of Science ®Google Scholar
• Joffe R T, Sokolov S T. Co-administration of fluoxetine and sumatriptan: the Canadian experience. Acta Psychiatrica Scandinavica 1997; 95: 551–552
   PubMed Web of Science ®Google Scholar
• Lundmark J, Gunnarsson T, Bengtsson F. A possible interaction between lithium and refecoxib. British Journal of Clinical Pharmocology 2002; 53: 403–404
   PubMedGoogle Scholar
• Martin J L, Barband M J, Schlaepfer T E, et al. Transcranial magnetic stimulation for treating depression. Cochrane Database of Systematic Reviews CD003493 2002; 2
   Google Scholar
• Maidment I D. Are fish oils an effective therapy in mental illness –an analysis of the data. Acta Psychiatrica Scandinavica 2000; 102: 3–11
   PubMed Web of Science ®Google Scholar
• Shaw K, Turner J, Del Mar C. Tryptophan and 5-hydroxytryptophan for depression. Cochrane Database of Systematic Reviews 2003; 3
   Google Scholar
• Jorm A F, Christensen H, Griffiths K M, Rodgers B. Effectiveness of complementary and self-help treatments for depression. Medical Journal of Ausstralia 2002; 176(Suppl.)S84–S96
   PubMed Web of Science ®Google Scholar
• Delgado P L. Approaches to the enhancement of patient adherence to antidepressant medication treatment. Journal of Clinical Psychiatry 2000; 61(Suppl.2)6–9
   PubMed Web of Science ®Google Scholar
• Parker G. Classifying depression. Should paradigms lost be regained?. American Journal of Psychiatry 2000; 157: 1195–1203
   PubMed Web of Science ®Google Scholar
• Parker G, Roy K, Mitchell P, Wilhelm K, Malhi G, Hadzi-Pavlovic D. Atypical depression: a reappraisal. American Journal of Psychiatry 2002; 159: 1470–1479
   PubMed Web of Science ®Google Scholar
• Stark P, Hardison C D. A review of multicenter controlled studies of fluoxetine vs. imipramine and placebo in outpatients with major depressive disorder. Journal of Clinical Psychiatry 1985; 46: 53–58
   PubMed Web of Science ®Google Scholar
• Cohn J B, Wilcox C S. Low-sedation potential of buspirone compared with alprazolam and lorazepam in the treatment of anxious patients: a double-blind study. Journal of Clinical Psychiatry 1986; 47: 409–412
   PubMedGoogle Scholar
• Brown W A, Arato M, Shrivastava R. Pituitary-adrenocortical hyperfunction and intolerance to fluvoxamine, a selective serotonin uptake inhibitor. American Journal of Psychiatry 1986; 143: 88–90
   PubMed Web of Science ®Google Scholar
• Elkin I, Shea M T, Watkins J T, et al. National Institute of Mental Health Treatment of Depression Collaborative Research Program. General effectiveness of treatments. Archives of General Psychiatry 1989; 146: 971–982
   Google Scholar
• Feighner J P, Boyer W F. Paroxetine in the treatment of depression: a comparison with imipramine and placebo. Acta Psychiatrica Scandinavica 1989; 350(Suppl.)125–129
   Google Scholar
• Lydiard R B, Laird L K, Morton W A, Jr, et al. Fluvoxamine, imipramine, and placebo in the treatment of depressed outpatients: effects on depression. Psychopharmacology Bulletin 1989; 25: 68–70
   PubMedGoogle Scholar
• Reimherr F W, Chouinard G, Cohn C K, et al. Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. Journal of Clinical Psychiatry 1990; 51(Suppl.B)18–27
   PubMed Web of Science ®Google Scholar
• Fontaine R, Ontiveros A, Elie R, et al. A double-blind comparison of nefazodone, imipramine, and placebo in major depression. Journal of Clinical Psychiatry 1994; 55: 234–241
   PubMed Web of Science ®Google Scholar
• Schweizer E, Feighner J, Mandos L A, et al. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. Journal of Clinical Psychiatry 1994; 55: 104–108
   PubMed Web of Science ®Google Scholar
• Rickels K, Schweizer E, Clary C, et al. Nefazodone and imipramine in major depression: a placebo-controlled trial. British Journal of Psychiatry 1994; 164: 802–805
   PubMedGoogle Scholar
• Doogan D P, Langdon C J. A double-blind, placebo-controlled comparison of sertraline and dothiepin in the treatment of major depression in general practice. International Clinical Psychopharmacology 1994; 9: 95–100
   PubMed Web of Science ®Google Scholar
• Bremner J D. A double-blind comparison of Org 3770, amitriptyline and placebo in major depression. Journal of Clinical Psychiatry 1995; 56: 519–525
   PubMedGoogle Scholar
• Fabre L, Birkhimer L J, Zaborny B A, Wong L F, Kapik B M. Fluvoxamine versus imipramine and placebo: a double-blind comparison in depressed patients. International Clinical Psychopharmacology 1996; 11: 119–127
   PubMedGoogle Scholar
• Cohn C K, Robinson D S, Roberts D L, et al. Responders to antidepressant drug treatment: a study comparing nefazodone, imipramine, and placebo in patients with major depression. Journal of Clinical Psychiatry 1996; 57(Suppl.2)15–18
   PubMedGoogle Scholar
• Lecrubier Y, Bourin M, Moon C A, et al. Efficacy of venlafaxine in depressive illness in general practice. Acta Psychiatrica Scandinavica 1997; 95: 485–493
   PubMed Web of Science ®Google Scholar
• Philipp M, Kohnen R, Hiller K O. Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks. (published erratum appears in BMJ 2000; 320: 361.). British Medical Journal 1999; 319: 1534–8
   PubMed Web of Science ®Google Scholar
• Muijen M D, Roy D, Silverstone T. A comparative clinical trial of fluoxetine, mianserin and placebo in depressed outpatients. Acta Psychiatrica Scandinavica 1988; 78: 384–390
   PubMedGoogle Scholar
• Rickels K, Amsterdam J, Clary C, et al. A placebo-controlled, double-blind, clinical trial of paroxetine in depressed outpatients. Acta Psychiatrica Scandinavica 1989; 350(Suppl.)117–123
   Google Scholar
• Laughren T P. The review of clinical safety data in a new drug application. Psychopharmacology Bulletin 1989; 25: 5–8
   PubMedGoogle Scholar
• Dunlop S R, Dornseif B E, Wernicke J F, et al. Pattern analysis shows beneficial effect of fluoxetine treatment in mild depression. Psychopharmacology Bulletin 1990; 26: 173–180
   PubMedGoogle Scholar
• Kiev A. A double-blind, placebo-controlled study of paroxetine in depressed outpatients. Journal of Clinical Psychiatry 1992; 53(Suppl.)27–29
   PubMedGoogle Scholar
• Smith W T, Glaudin V. A placebo-controlled trial of paroxetine in the treatment of major depression. Journal of Clinical Psychiatry 1992; 53: 36–39
   PubMedGoogle Scholar
• Claghorn J L. The safety and efficacy of paroxetine compared with placebo in a double-blind trial of depressed outpatients. Journal of Clinical Psychiatry 1992; 53(Suppl.)33–35
   PubMedGoogle Scholar
• Heiligenstein J H, Tollefson G D, Faries D E. A double-blind trial of fluoxetine, 20mg and placebo in outpatients with DSM-III-R major depression and melancholia. International Clinical Psychopharmacology 1993; 8: 247–251
   PubMedGoogle Scholar
• Fabre L BL, Birkhimer L J, Zaborny B A, Wong L F, Kapik B M. Fluvoxamine versus imipramine and placebo: a double-blind comparison in depressed patients. International Clinical Psychopharmacology 1996; 11: 119–127
   PubMedGoogle Scholar
• Massana J. Reboxetine versus fluoxetine. an overview of efficacy and tolerability. Journal of Clinical Psychiatry 1998; 59(Suppl.)8–10
   PubMedGoogle Scholar
• Olie J P, Gunn K P, Katz E. A double-blind placebo-controlled mulitcentre study of sertraline in the acute and continuation treatment of major depression. European Psychiatry 1997; 12: 34–41
   PubMedGoogle Scholar
• Schweizer E, Feighner J, Mandos L A, Rickels K. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. Journal of Clinical Psychiatry 1994; 55: 104–108
   PubMed Web of Science ®Google Scholar
• Thase M E, Venlafaxine XR 207 Study Group. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. Journal of Clinical Psychiatry 1997; 58: 393–398
   PubMed Web of Science ®Google Scholar
• Rudolph R L, Fabre L F, Feighner J P, Rickels K, Entsuah R, Derivan A T. A randomised, placebo-controlled, dose–response trial of venlafaxine hydrochloride in the treatment of major depression. Journal of Clinical Psychiatry 1998; 59: 116–122
   PubMed Web of Science ®Google Scholar
• Kahn A, Upton G V, Rudolph R L, Entsuah R, Leventer S M, Venlafaxine Investigator Study Group. The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: A dose–response study. Journal of Clinical Psychopharmacology 1998; 18: 19–25
   PubMedGoogle Scholar
• Rudolph R L, Feiger A D. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. Journal of Affective Disorders 1999; 56: 171–181
   PubMed Web of Science ®Google Scholar
• Smith W T, Glaudin V, Panagides J, et al. Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder. Psychopharmacology Bulletin 1990; 26: 191–196
   PubMedGoogle Scholar
• Feighner J, Targum S D, Bennett M E, et al. A double-blind, placebo-controlled trial of nefazodone in the treatment of patients hospitalized for major depression. Journal of Clinical Psychiatry 1998; 59: 246–253
   PubMedGoogle Scholar
• de Jong R, Treiber R, Henrich G. Effectiveness of two psychological treatments for inpatients with severe and chronic depression. Cognitive Therapy Research 1988; 10: 645–663
   Google Scholar
• Lydiard R B, Laird L K, Morton W A, Jr. Fluvoxamine, imipramine, and placebo in the treatment of depressed outpatients: effects on depression. Psychopharmacology Bulletin 1989; 25: 68–70
   PubMedGoogle Scholar
• Tignol J, Stoker M J, Dunbar G C. Paroxetine in the treatment of melancholia and severe depression. International Clinical Psychopharmacology 1992; 7: 91–94
   PubMed Web of Science ®Google Scholar
• Roose S P, Glassman A H, Attia E, Woodring S. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. American Journal of Psychiatry 1994; 151: 1735–1739
   PubMed Web of Science ®Google Scholar
• Kasper S, Moller H-J, Montgomery S A, Zondag E. Antidepressant efficacy in relation to item analysis and severity of depression: A placebo-controlled trial of fluvoxamine versus imipramine. International Clinical Psychopharmacology 1995; 9(Suppl.4)3–12
   PubMedGoogle Scholar
• Lepine J P, Goger J, Blashko C, et al. A double-blind study of the efficacy and safety of sertraline and clomipramine in outpatients with severe major depression. International Clinical Psychopharmacology 2000; 15: 263–271
   PubMedGoogle Scholar
• Guelfi J D, Payan C, Fermanian J, et al. Moclobemide versus clomipramine in endogenous depression. A double-blind randomised clinical trial. British Journal of Psychiatry 1992; 160: 519–524
   PubMedGoogle Scholar
• Clerc G E, Ruimy P, Verdeau-Palles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. International Journal of Psychopharmacology 1994; 9: 139–143
   PubMed Web of Science ®Google Scholar
• Tzanakaki M, Guazzelli M, Nimatoudis I, Zissis N P, Smeraldi E, Rizzo F. Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia. [erratum appears in International Clinical Psychopharmacology 2000; 15: 120.]. International Clinical Psychopharmacology 2000; 15: 29–34
   PubMed Web of Science ®Google Scholar
• Feiger A, Kiev A, Shrivastava R K, Wisselink P G, Wilcox C S. Nefazadone versus sertraline in outpatients with major depression: Focus on efficacy, tolerability and effects on sexual function and satisfaction. Journal of Clinical Psychiatry 1996; 57(Suppl.2)53–62
   PubMed Web of Science ®Google Scholar
• Feighner J P. A comparative trial of fluoxetine and amitriptyline in patients with major depressive disorder. Journal of Clinical Psychiatry 1985; 46: 369–372
   PubMed Web of Science ®Google Scholar
• Fawcett J, Zajecka J M, Kravitz H M, et al. Fluoxetine versus amitriptyline in adult outpatients with major depression. Current Therapeutic Research 1989; 45: 821–831
   Web of Science ®Google Scholar
• Guillibert E, Pelicier Y, Archambault J C, et al. A double-blind, multicentre study of paroxetine versus clomipramine in depressed elderly patients. Acta Psychiatrica Scandinavica 1989; 350(Suppl.)132–134
   Google Scholar
• Levine S, Deo R, Mahadevan K. A comparative trial of a new antidepressant, fluoxetine. International Clinical Psychopharmacology 1989; 4(Suppl.1)41–45
   PubMedGoogle Scholar
• Perry P J, Garvey M J, Kelly M W, Cook B L, Dunner F J, Winokur G. A comparative trial of fluoxetine versus trazodone in outpatients with major depression. Journal of Clinical Psychiatry 1989; 50: 290–294
   PubMed Web of Science ®Google Scholar
• Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Journal of Affective Disorders 1990; 18: 289–299
   PubMed Web of Science ®Google Scholar
• Dowling B, Webb M GT, Halpin C M, et al. Fluoxetine: a comparative study with dothiepin. Irish Journal of Psychiatry 1990; Spring: 3–7
   Google Scholar
• Keegan D, Bowen R C, Blackshaw S, et al. A comparison of fluoxetine and amitriptyline in the treatment of major depression. International Clinical Psychopharmacology 1991; 6: 117–124
   PubMedGoogle Scholar
• Hutchinson D R, Tong S, Moon C A, et al. Paroxetine in the treatment of elderly depressed patients in general practice: a double-blind comparison with amitriptyline. International Clinical Psychopharmacology 1992; 6(Suppl.4)43–51
   PubMedGoogle Scholar
• Bignamini A, Rapisarda V. A double-blind multicentre study of paroxetine and amitriptyline in depressed outpatients. Italian Paroxetine Study Group. International Clinical Psychopharmacology 1992; 6(Suppl.4)37–41
   PubMedGoogle Scholar
• Ohrberg S, Christiansen P E, Severin B, et al. Paroxetine and imipramine in the treatment of depressive patients in psychiatric practice. Acta Psychiatrica Scandinavica 1992; 86: 437–444
   PubMed Web of Science ®Google Scholar
• Bowden C L, Schatzberg A F, Rosenbaum A, et al. Fluoxetine and desipramine in major depressive disorder. Journal of Clinical Psychopharmacology 1993; 13: 305–311
   PubMed Web of Science ®Google Scholar
• Beasley C M, Jr, Sayler M E, Potvin J H. Fluoxetine versus amitriptyline in the treatment of major depression: a multicenter trial. International Clinical Psychopharmacology 1993; 8: 143–149
   PubMedGoogle Scholar
• Moller H J, Berzewski H, Eckmann F, et al. Double-blind multicenter study of paroxetine and amitriptyline in depressed inpatients. Pharmacopsychiatry 1993; 26: 75–78
   PubMedGoogle Scholar
• Rosenberg C, Damsbo N, Fuglum E, et al. Citalopram and imipramine in the treatment of depressive patients in general practice. A Nordic multicentre clinical study. International Clinical Psychopharmacology 1994; 9: 41–48
   PubMedGoogle Scholar
• Doogan D P, Langdon C J. A double-blind, placebo-controlled comparison of sertraline and dothiepin in the treatment of major depression in general practice. International Clinical Psychopharmacology 1994; 9: 95–100
   PubMed Web of Science ®Google Scholar
• Stuppaeck C H, Geretsegger C, Whitworth A B, et al. A multicenter double-blind trial of paroxetine versus amitriptyline in depressed inpatients. Journal of Clinical Psychopharmacology 1994; 14: 241–246
   PubMed Web of Science ®Google Scholar
• Staner L, Kerkhofs M, Detroux D, et al. Acute, subchronic and withdrawal sleep EEG changes during treatment with paroxetine and amitriptyline: a double-blind randomized trial in major depression. Sleep 1995; 18: 470–477
   PubMed Web of Science ®Google Scholar
• Ravindran A V, Judge R, Hunter B N, et al. A double-blind, multicenter study in primary care comparing paroxetine and clomipramine in patients with depression and associated anxiety. Paroxetine Study Group. Journal of Clinical Psychiatry 1997; 58: 112–118
   PubMed Web of Science ®Google Scholar
• Fournier J P, Lane R M, Chouinard D B, et al. A double-blind comparison of sertraline and imipramine in outpatients with major depression. Human Psychopharmacology 1997; 12: 203–215
   Google Scholar
• Taragano F E, Lyketsos C G, Mangone C A, Allegri R F, Comesana-Diaz E. A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer's disease. Psychosomatics 1997; 38: 246–252
   PubMed Web of Science ®Google Scholar
• Berzewski H, Van Moffaert M, Gagiano C A. Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive offsodes. European Neuropsychopharmacology 1997; 7(Suppl.1)s37–s47
   PubMedGoogle Scholar
• Keller M B, Gelenberg A J, Hirschfeld R M, et al. The treatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipramine. Journal of Clinical Psychiatry 1998; 59: 598–607
   PubMed Web of Science ®Google Scholar
• Nelson J C, Kennedy J S, Pollock B G, et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. American Journal of Psychiatry 1999; 156: 1024–1028
   PubMed Web of Science ®Google Scholar
• Hoehn-Saric R, Ninan P, Black D W, et al. Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive–compulsive and major depressive disorders. Archives of General Psychiatry 2000; 57: 76–82
   PubMed Web of Science ®Google Scholar
• Gentil V, Kerr-Correa F, Moreno R, et al. Double-blind comparison of venlafaxine and amitriptyline in outpatients with major depression with or without melancholia. Journal of Psychophamacology 2000; 14: 61–66
   PubMedGoogle Scholar
• Dierick M, Ravizza L, Realini R, et al. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Progress in Neuropsychopharmacology and Biological Psychiatry 1996; 20: 57–71
   PubMed Web of Science ®Google Scholar
• Tylee A, Beaumont G, Bowden M W, et al. A double-blind, randomised, 12-week comparison study of the safety and the efficacy of venlafaxine and fluoxetine in moderate to severe major depression in general practice. Primary Care Psychiatry 1997; 3: 51–58
   Google Scholar
• Costae Silva J. Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression. Journal of Clinical Psychiatry 1998; 59: 352–357
   PubMedGoogle Scholar
• Poirier M F, Boyer P. Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison. British Journal of Psychiatry 1999; 175: 12–16
   PubMed Web of Science ®Google Scholar
• Mehtonen O P, Sogaard J, Roponen P, Behnke K. Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Venlafaxine 631 Study Group. Journal of Clinical Psychiatry 2000; 61: 95–100
   PubMed Web of Science ®Google Scholar
• Zivlov M, de Jongh G D. A 6-week randomised, double-blind multicentre trial in hospitalised depressed patients. Human Psychopharmacology 1995; 10: 173–180
   Google Scholar
• Halikas J A. Org 3770 (mirtazapine) versus trazodone: a placebo controlled trial in depressed elderly patients. Human Psychopharmacology 1995; 10(Suppl.2)125–133
   Google Scholar
• Richou H, Ruimy P, Charbaut J. A multicentre double-blind, clomipramine controlled efficacy and safety study of Org 3770. Human Psychopharmacology 1995; 10: 263–271
   Web of Science ®Google Scholar
• Rush A J, Armitage R, Gillin J C, et al. Comparative effects of nefazodone and fluoxetine on sleep in outpatients major depressive disorder. Biological Psychiatry 1998; 44: 3–14
   PubMed Web of Science ®Google Scholar
• Geerts S, Bruynooghe F, De Cuyper H, et al. Moclobemide versus fluoxetine for major depressive episodes. Clinical Neuropharmacology 1994; 17(Suppl.1)50–57
   Google Scholar
• Ramaekers J G, Ansseau M, Muntjewerff N D, et al. Considering the P450 cytochrome system as determining combined effects of antidepressants and benzodiazepines on actual driving performance of depressed outpatients. International Clinical Psychopharmacology 1997; 12: 159–169
   PubMedGoogle Scholar
• Lapierre Y D, Joffe R, McKenna K, et al. Moclobemide versus fluoxetine in the treatment of major depressive disorders in adults. Journal of Psychiaty and Neuroscience 1997; 22: 118–126
   PubMedGoogle Scholar
• Keller M B, McCullough J P, Klein D N, et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. New England Journal of Medicine 2000; 342: 1462–1470
   PubMed Web of Science ®Google Scholar
• Katona C L, Abou-Saleh M T, Harrison D A, et al. Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. British Journal of Psychiatry 1995; 166: 80–86
   PubMed Web of Science ®Google Scholar
• Fava M, Rosenbaum J F, McGrath P J, Stewart J W, Amsterdam J D, Quitkin F M. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. American Journal of Psychiatry 1994; 151: 1372–1374
   PubMed Web of Science ®Google Scholar
• Baumann P, Nil R, Souche A, et al. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. Journal of Clinical Psychopharmacology 1996; 16: 307–314
   PubMed Web of Science ®Google Scholar
• Prange A J, Jr, Wilson I C, Rabon A M, Lipton M A. Enhancement of imipramine antidepressant activity by thyroid hormone. American Journal of Psychiatry 1969; 126: 457–469
   PubMed Web of Science ®Google Scholar
• Goodwin F K, Prange AJ Jr, Post R M, Muscettola G, Lipton M A. Potentiation of antidepressant effects by 1-triiodothyronine in tricyclic nonresponders. American Journal of Psychiatry 1982; 139: 34–38
   PubMed Web of Science ®Google Scholar
• Thase M E, Kupfer D J, Frank E, Jarrett D B. Treatment of imipramine-resistant recurrent depression. II. An open clinical trial of lithium augmentation. Journal of Clinical Psychiatry 1989; 50: 385–388
   PubMed Web of Science ®Google Scholar
• Steiner M, Radwan M, Elizur A, Blum I, Atsmon A, Davidson S. Failure of 1-triiodothyronine to potentiate tricylic antidepressant response. Current Therapeutic Research 1978; 23: 655–659
   Google Scholar
• Joffe R T, Singer W, Levitt A J, MacDonald C. A placebocontrolled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Archives of General Psychiatry 1993; 50: 387–393
   PubMed Web of Science ®Google Scholar
• Perez V, Soler J, Puigdemont D, Alvarez E, Artigas F. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius. Archives of General Psychiatry 1999; 56: 375–379
   PubMed Web of Science ®Google Scholar
• Artigas F, Perez V, Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Archives of General Psychiatry 1994; 51: 248–251
   PubMed Web of Science ®Google Scholar
• Tome M B, Isaac M T. Cost-benefit and cost-effectiveness analysis of the rapid onset of selective serotonin reuptake inhibitors by augmentation. International Journal of Psychiatry in Medicine 1998; 27: 377–390
   Google Scholar
• Bordet R, Thomas P, Dupuis B. Effect of pindolol on onset of action of paroxetine in the treatment of major depression: intermediate analysis of a double-blind, placebo-controlled trial. Reseau de Recherche et D'experimentation Psychopharmacologique. American Journal of Psychiatry 1998; 155: 1346–1351
   PubMed Web of Science ®Google Scholar
• Tome M B, Isaac M T, Harte R, Holland C. Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. International Clinical Psychopharmacology 1997; 12: 81–89
   PubMed Web of Science ®Google Scholar
• Berman R M, Darnell A M, Miller H L, Anand A, Charney D S. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebocontrolled trial. American Journal of Psychiatry 1997; 154: 37–43
   PubMedGoogle Scholar
• Moreno F A, Gelenberg A J, Bachar K, Delgado P L. Pindolol augmentation of treatment-resistant depressed patients. Journal of Clinical Psychiatry 1997; 58: 437–439
   PubMed Web of Science ®Google Scholar
• Maes M, Vandoolaeghe E, Ranjan R, et al. Increased serum soluble CD8 or suppressor/cytotoxic antigen concentrations in depression: suppressive effects of glucocorticoids. Biological Psychiatry 1996; 40: 1273–1281
   PubMedGoogle Scholar
• Sacristan J A, Gilaberte I, Boto B, et al. Cost-effectiveness of fluoxetine plus pindolol in patients with major depressive disorder: results from a randomized, double-blind clinical trial. International Clinical Psychopharmacology 2000; 15: 107–113
   PubMed Web of Science ®Google Scholar
• Perez V, Gilaberte I, Faries D, Alvarez E, Artigas F. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 1997; 349: 1594–1597
   PubMed Web of Science ®Google Scholar
• Zanardi R, Artigas F, Franchini L, et al. How long should pindolol be associated with paroxetine to improve the antidepressant response?. Journal of Clinical Psychopharmacology 1997; 17: 446–450
   PubMed Web of Science ®Google Scholar
• Zanardi R, Franchini L, Gasperini M, Lucca A, Smeraldi E, Perez J. Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: a controlled study. Journal of Clinical Psychopharmacology 1998; 18: 441–446
   PubMed Web of Science ®Google Scholar
• Maes M, Libbrecht I, van Hunsel F, Campens D, Meltzer H Y. Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. Journal of Clinical Psychopharmacology 1999; 19: 177–182
   PubMed Web of Science ®Google Scholar
• Montgomery S A, Dufour H, Brion S, et al. The prophylactic efficacy of fluoxetine in unipolar depression. British Journal of Psychiatry Supplement 1988; 3: 69–76
   Google Scholar
• Montgomery S A, Rasmussen J G, Tanghoj P. A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression. International Clinical Psychopharmacology 1993; 8: 181–188
   PubMed Web of Science ®Google Scholar
• Robert P, Montgomery S A. Citalopram in doses of 20–60 mg is effective in depression relapse prevention: a placebo-controlled 6 month study. International Clinical Psychopharmacology 1995; 10(Suppl.1)29–35
   PubMedGoogle Scholar
• Montgomery S A, Dunbar G. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. International Clinical Psychopharmacology 1993; 8: 189–195
   PubMed Web of Science ®Google Scholar
• Gilaberte I, Montejo A L, de la Gandara J, et al. Fluoxetine in the prevention of depressive recurrences: a double-blind study. Journal of Clinical Psychopharmacology 2001; 21: 417–424
   PubMed Web of Science ®Google Scholar
• Kovacs M, Rush A J, Beck A T, Hollon S D. Depressed outpatients treated with cognitive therapy or pharmacotherapy. Archives of General Psychiatry 1981; 38: 33–39
   PubMed Web of Science ®Google Scholar
• Frank E, Kupfer D J, Perel J M, et al. Three-year outcomes for maintenance therapies in recurrent depression. Archives of General Psychiatry 1990; 47: 1093–1099
   PubMed Web of Science ®Google Scholar
• Fava G A, Grandi S, Zielezny M, Canestrari R, Morphy M A. Cognitive behavioral treatment of residual symptoms in primary major depressive disorder. American Journal of Psychiatry 1994; 151: 1295–1299
   PubMed Web of Science ®Google Scholar
• Paykel E S, Scott J, Teasdale J D, et al. Prevention of relapse in residual depression by cognitive therapy: a controlled trial. Archives of General Psychiatry 1999; 56: 829–835
   PubMed Web of Science ®Google Scholar
• Blackburn I M, Moore R G. Controlled acute and follow-up trial of cognitive therapy and pharmacotherapy in out-patients with recurrent depression. British Journal of Psychiatry 1997; 171: 328–334
   PubMed Web of Science ®Google Scholar
• Halama P. Wirksamkeit des Johanniskrautextraktes LI 160 bei depressiver Verstimmung. Nervenheilkunde 1991; 10: 250–253
   Google Scholar
• Reh C, Laux P, Schenk N. Hypericum-Extrakt bei depressionen –eine wirksame alternative. Therapiewoche 1992; 42: 1576–1581
   Google Scholar
• Hansgen K D, Vesper J, Ploch M. Multicenter double-blind study examining the antidepressant effectiveness of the hypericum extract LI 160. Journal of Geriatric Psychiatry and Neurology 1994; 7(Suppl.1)S15–S18
   Google Scholar
• Laakmann G, Schule C, Baghai T, St. Kieser M. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry 1998; 31(Suppl.1)54–59
   PubMed Web of Science ®Google Scholar
• Schrader E, Meir B, Brattstrom A. Hypericum treatment of the mild-moderate depression in a placebo-controlled study. A prospective, bouble-blind, randomised, placebo-controlled, multicentre study. Human Psychopharmacology 1998; 13: 163–169
   Web of Science ®Google Scholar
• Woelk H. Comparison of St John's wort and imipramine for treating depression: Randomised controlled trial. British Medical Journal 2000; 321: 536–539
   PubMed Web of Science ®Google Scholar
• Shelton R C, Keller M B, Gelenberg A, et al. Effectiveness of St John's Wort in major depression: a randomised controlled trial. Journal of the American Medical Association 2001; 285: 1978–1986
   PubMed Web of Science ®Google Scholar
• Lecrubier Y, Clerc G, Didi R, Kieser M. Efficacy of St. John's wort extract WS 5570 in major depression: a double-blind. placebo-controlled trial. American Journal of Psychiatry 2002; 159: 1361–1366
   PubMed Web of Science ®Google Scholar
• Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St John's Wort) in major depressive disorder: a randomized controlled trial. Journal of the American Medical Association 2002; 287: 1807–1814
   PubMed Web of Science ®Google Scholar
• Schrader E. Equivalence of St John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression. International Clinical Psychopharmacology 2000; 15: 61–68
   PubMed Web of Science ®Google Scholar
• Harrer G, Hubner W D, Podzuweit H. Effectiveness and tolerance of the hypericum extract LI 160 compared to maprotiline: a multicenter double-blind study. Journal of Geriatric Psychiatry and Neurology 1994; 7(Suppl.1)S24–S28
   Google Scholar
• Wheatley D. LI 160, an extract of St. John's wort, versus amitriptyline in mildly to moderately depressed outpatients –a controlled 6-week clinical trial. Pharmacopsychiatry 1997; 30(Suppl.2)77–80
   PubMedGoogle Scholar
• Vorbach E U, Arnoldt K H, Hubner W D. Efficacy and tolerability of St. John's wort extract LI 160 versus imipramine in patients with severe depressive episodes according to ICD-10. Pharmacopsychiatry 1997; 30(Suppl.2)81–85
   PubMed Web of Science ®Google Scholar